A deeply discounted, high-risk turnaround: Nu Skin is betting its future on AI-personalized beauty-tech devices that convert one-time sales into recurring wellness subscriptions.
Overview
Nu Skin is in a difficult transition, attempting to reinvent itself from a traditional direct-selling/MLM company into an “intelligent beauty and wellness platform” built on social commerce and data-driven personalization. FY2025 revenue fell to ~$1.485B (-14% YoY), driven by weakness in key Asian markets (notably Mainland China and South Korea) and deterioration in field metrics (active customers down ~10%; Sales Leaders down ~19%), which threatens future sales capacity. Profitability rebounded sharply, but headline net income (~$160M) was heavily boosted by a one-time pre-tax gain (~$176M) from the Mavely divestiture; adjusted EPS (~$1.27) better reflects core improvement from cost actions under “Project Accelerate.” The business remains anchored by premium brands (Nu Skin, Pharmanex, ageLOC) and a device-led “razor-and-blade” model, with technology assets (Biophotonic Scanner history; Vera app; Prysm iO) positioned to drive recurring revenue if adoption and subscription conversion succeed.